Quantcast
Connect with us

US approves new trial of embryonic stem cells on blindness

Published

on

US biotech company Advanced Cell Technology said Monday it was cleared by the government to start its second trial using human embryonic stem cells to treat blindness, this time in older people.

The trial will examine the therapy’s ability to safely treat people with a condition known as dry age-related macular degeneration, the most common form of irreversible vision loss in people over age 60.

ADVERTISEMENT

There is currently no cure for the disease, which affects around 10-15 million Americans and another 10 million people in Europe, the company said.

The Food and Drug Administration cleared the Massachusetts-based company in November to begin a similar trial on patients with a less common form of juvenile vision loss, known as Stargardt’s disease.

“ACT is now the first company to receive FDA clearance for two hESC (human embryonic stem cell) trials, and is now a true translational leader in the field of regenerative medicine,” said chief executive Gary Rabin.

“It marks a major step forward, not just within the stem cell sector, but, potentially for modern healthcare techniques.”

The company hopes to begin the US clinical trials in the coming months, and intends to seek approval for similar trials in Europe. The US and European market for such a treatment amounts to 25 to 30 billion dollars, it said.

ADVERTISEMENT

“We are moving ahead aggressively to seek regulatory clearance from the European Medicines Agency to conduct clinical trials in Europe,” said Edmund Mickunas, ACT?s Vice President of Regulatory Affairs.

ACT’s announcement marks the third such trial of embryonic stem cells in human patients, after US company Geron broke new ground in October last year with the first-ever attempt to use the therapy on a human patient with spinal cord injury.

Embryonic stem cell research has been a controversial field ever since the first such stem cells were isolated more than 12 years ago. Critics oppose the research because it involves the destruction of human embryos.

ADVERTISEMENT

However scientists say the cells offer great promise in treating Parkinson’s disease, diabetes and a variety of other illnesses.

Like the other trials involving human patients, the first step in ACT’s Phase I and II trials is to assess whether the therapy is safe before moving on to testing how well it works.

ADVERTISEMENT

Bob Lanza, chief scientist at ACT, said that trials using the technique on animals have shown no evidence of complication or tumors.

“In a rat model of macular degeneration, we have seen a remarkable improvement in visual performance over untreated animals, without any adverse effects,” said Lanza.

Twelve patients will enroll in the study at various US sites including the University of California, Los Angeles (UCLA) and Stanford University.

ADVERTISEMENT

The therapy uses retinal pigment epithelial (RPE) cells derived from human embryonic stem cells to replace RPE cells that have broken down in patients with the disease.

Dry age-related macular degeneration, the type that occurs in 90 percent of cases, causes a deterioration in central vision when RPE cells in the patient’s macula, in the center of the retina, lose their ability to function.

Patients often experience blurring in the center of their field of vision, while peripheral view remains intact.

Dry AMD gets progressively worse, while the other type, known as wet AMD, does not advance in stages. Wet AMD is caused by abnormal blood vessels which leak fluid behind the macula, causing a quicker loss of central vision.

ADVERTISEMENT

“As the population ages, the incidence of AMD is expected to double over the next 20 years, further exacerbating this unmet medical need,” Lanza said.


Report typos and corrections to: [email protected].
READ COMMENTS - JOIN THE DISCUSSION
Continue Reading

Breaking Banner

‘Why do we need camo in space’: Trump’s Space Force ridiculed for woodland camouflage uniforms

Published

on

On Friday, the United States Space Force released an image of their new uniforms on Twitter.

The image shows a Battle Dress Uniform (BDU) for a four-star general in a woodland camouflage pattern, with a matching camo nametape.

https://twitter.com/SpaceForceDoD/status/1218335200964464650

However, many people were confused as to why the Space Force would use uniforms designed to blend in on earth.

Here's some of what people were saying:

https://twitter.com/PostCultRev/status/1218351691021484032

Sorry for the question but why do we need camo in space?

Continue Reading

Breaking Banner

BUSTED: National Archives caught doctoring exhibit to remove criticism of President Trump from women

Published

on

The National Archives were caught editing an artifact from the Trump administration to remove criticism of the president, according to a bombshell new report in The Washington Post.

The newspaper reported on a "large color photograph" at the National Archives exhibit marking the centennial of women's suffrage.

"The 49-by-69-inch photograph is a powerful display. Viewed from one perspective, it shows the 2017 march. Viewed from another angle, it shifts to show a 1913 black-and-white image of a women’s suffrage march also on Pennsylvania Avenue. The display links momentous demonstrations for women’s rights more than a century apart on the same stretch of pavement. But a closer look reveals a different story," the newspaper noted.

Continue Reading
 

Breaking Banner

Dershowitz is running a ‘bizarro defense’ of Trump: Harvard Law colleague says ‘Alan is just completely wacko’

Published

on

Two of the most famous names associated with Harvard Law School had competing appearances on MSNBC on Friday.

It began when Alan Dershowitz, a professor emeritus, was interviewed MSNBC chief legal correspondent Ari Melber about his new role officially representing President Donald Trump during the Senate impeachment trial.

Dershowitz claimed that neither abuse of power nor obstruction of Congress count as "high crimes" under the constitution.

Professor Alan Dershowitz, who has also been associated with Harvard Law for five decades, was asked about Dershowitz's argument during an interview with Chris Hayes.

Continue Reading
 
 
Help Raw Story Uncover Injustice. Join Raw Story Investigates for $1 and go ad-free.
close-image